-
CStone Pharmaceuticals announces joint development of loratinib with Pfizer in ROS1-positive advanced lung cancer
Time of Update: 2021-06-22
Article source: Medical Rubik's Cube InfoOn June 15th, CStone Pharmaceuticals announced that it would cooperate with Pfizer on ROS1-positive advanced non-small cell lung cancer (NSCLC) in Greater China to jointly develop lorlatinib .
-
The vice president of a drug company who drunk driving was taken criminal coercive measures
Time of Update: 2021-06-22
issued a reminder announcement on the criminal compulsory measures taken by the company's deputy general manager for drunk driving .
Li Haibing, the deputy general manager of the company, that he was informed that he may be subject to further criminal compulsory measures due to drunk driving.
-
Another medicine mining alliance is here!
Time of Update: 2021-06-22
Medicine Medicine Medicine Medical institutions should give priority to the use of selected drugs, strictly implement the selected prices, and ensure that the agreed purchase volume is completed .
-
Resignation of the chairman, some directors and general manager of Tianyao Pharmaceutical
Time of Update: 2021-06-22
Zhang Jie applied to resign from the company’s eighth board of directors and directors, Mr.
Yang Fuzhen applied to resign from the company’s eighth board of directors and general manager Position .
-
The long-term efficacy was higher than that of Theo-American Aibervi JAK Inhibitor Phase 3 clinical results
Time of Update: 2021-06-22
Note: There are limitations in the original textResources:[1] New Long-Term Efficacy and Safety Analyses Evaluating RINVOQ® (upadacitinib) in Patients with Rheumatoid Arthritis to be Presented at EULAR 2021 Virtual Congress.
com/news/press-releases/new-long-term-efficacy-and-safety-analyses-evaluating-rinvoq-upadacitinib-in-patients-with-rheumatoid-arthritis-to-be-presented-at-eular-2021-virtual-congress.
htm[2] AbbVie to Present Analysis Evaluating Continuous RINVOQ® (upadacitinib) Treatment in Psoriatic Arthritis for More Than One Year at EULAR 2021 Virtual Congress.
com/news/press-releases/abbvie-to-present-analysis-evaluating-continuous-rinvoq-upadacitinib-treatment-in-psoriatic-arthritis-for-more-than-one-year-at-eular-2021-virtual-congress.
-
Sales of 37 medicines suspended in high-risk areas in Guangdong, "yellow code" customers are not allowed to buy medicines in stores
Time of Update: 2021-06-22
The "Notice" requires that drug retail companies in the province further implement the real-name registration and reporting system for drugs in the "Catalog", requiring customers to enter the store to take their temperature and show their health code.
-
The US FDA accelerates the approval of innovative treatments for Alzheimer's disease!
Time of Update: 2021-06-22
Although at the meeting of the Peripheral and Central Nervous System Drug Advisory Committee in November 2020, the experts of the committee had different voices on the clinical benefits, but based on clinical trials, it is clear that the use of Aduhelm treatment can significantly reduce amyloid plaques In the end, the US FDA followed the institutional process of the accelerated approval mechanism and determined that Aduhelm met the regulatory requirements for accelerated approval .
-
Announcement of the results of the planned selection of Shanghai centralized drug procurement (SH-DL2021-1)
Time of Update: 2021-06-22
Publicity time: June 8, 2021 to June 10, 2021According to the content of the announcement, the results of the proposed selection include 9 specifications including Olanzapine and Gefitinib .
Attachment: Shanghai Centralized Pharmaceutical Procurement (SH-DL2021-1) Proposed Selection Results
-
Li Haibing, deputy general manager of Beilu Pharmaceutical, resigns
Time of Update: 2021-06-22
Li Haibing and applied for resignation from his position as deputy general manager .
Li Haibing's resignation report will take effect from the date of delivery to the company's board of directors, and his resignation will not affect the company's normal operations .
-
Pioneer Pharmaceuticals Prokalamide's Phase III clinical trial for the treatment of COVID-19 was approved by Brazil's ANVISA
Time of Update: 2021-06-22
announced that its Phase III clinical trial of Prokalamide for the treatment of male patients with mild and moderate new coronary disease has been formally approved by the Brazilian drug regulatory agency ANVISA on June 11, local time .
-
Tetrabenazine tablets are approved soon for the treatment of Huntington's disease
Time of Update: 2021-06-22
1 new drug tetrabenazine tablets (the relevant acceptance number is JXHS2000123/124), and it is expected to be officially approved soon and become the second domestic approval.
-
BeiGene Baizean's new indications for listing application are accepted in China
Time of Update: 2021-06-22
BeiGene announced today that the NMPA Drug Evaluation Center has accepted its anti-PD-1 antibody drug Bezan for the treatment of previously treated, locally advanced unresectable or metastatic highly microsatellite unstable (MSI-H) or wrong Application for new indications for patients with solid tumors with defective repair (dMMR) .
-
2020 Statistical Communiqué on the Development of National Medical Security Undertakings
Time of Update: 2021-06-22
4% of the year’s GDP; the total expenditure of the national basic medical insurance fund (including maternity insurance) was 21,032 billion yuan, a year-on-year increase of 1.
-
The State Food and Drug Administration issued an announcement on the addition of relevant information in the instructions of haloperidol tablets
Time of Update: 2021-06-22
According to research and demonstration, the instructions of drugs such as haloperidol tablets (Annex 1) can increase the number of children and the usage and dosage as required .
-
The United States approves the first Alzheimer's disease drug in the past 20 years at an annual cost of 56,000 US dollars
Time of Update: 2021-06-22
S. Food and Drug Administration (FDA) issued a statement on its official website stating that it approved the Aduhelm (aducanumab) developed by the pharmaceutical company Biogen to treat patients with Alzheimer’s disease.
It is the first new treatment approved for Alzheimer's disease since 2003 .
-
Healthyuan Omeprazole Sodium for Injection Passed the Consistency Evaluation of Generic Drugs
Time of Update: 2021-06-22
On June 15th, Joincare announced that Livzon Pharmaceutical Factory, a wholly-owned subsidiary, received the "Drug Supplement Application Approval Notice" approved and issued by the National Medical Products Administration.
The omeprazole sodium for injection produced by Livzon Pharmaceutical Factory passed Consistency evaluation of the quality and efficacy of generic drugs .
-
ASCO annual meeting grand opening!
Time of Update: 2021-06-22
According to reports, the RATIONALE 302 study is a randomized, open, multi-center, global phase 3 clinical trial designed to evaluate tislelizumab versus chemotherapy selected by investigators as the second-line treatment for patients with advanced or metastatic esophageal squamous cell carcinoma Effectiveness and safety .
-
10 Chinese products are shortlisted for the new crown antigen reagent list of the British Ministry of Health
Time of Update: 2021-06-22
The updated list shows that 24 new coronavirus antigen reagents have passed the verification, and 10 of them are manufactured by Chinese companies, including Oriental Bio, Deep Blue Medical, Daiernuosi, Shuo Shi biological, Acon biology, biotechnology and other egg-based products .
-
Viewing the Investment Choice of Pharmaceutical Enterprises from Yunnan Baiyao
Time of Update: 2021-06-22
In 2020, the income from changes in the fair value of Fosun Pharma's financial assets was 559 million yuan, ranking fourth among A-share listed pharmaceutical companies; investment income was 2.
-
Eli Lilly's oral JAK inhibitor Olumiant effectively improves pain / body function / morning stiffness of joints
Time of Update: 2021-06-22
Olumiant is a tyrosine protein kinase (JAK) 1/2 inhibitor, administered orally once a day, suitable for moderate to severe patients with poor efficacy or intolerance to one or more disease-improving anti-rheumatic drugs (DMARD) Adult patients with active rheumatoid arthritis can be used in combination with methotrexate or other non-biological anti-rheumatic drugs .
